Trial Profile
A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of two
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PePS2
- 28 Nov 2023 Planned End Date changed from 1 Jan 2023 to 7 Feb 2024.
- 16 Nov 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
- 16 Nov 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.